313 related articles for article (PubMed ID: 31505038)
21. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
22. Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis.
Glaser F; John C; Engel B; Höh B; Weidemann S; Dieckhoff J; Stein S; Becker N; Casar C; Schuran FA; Wieschendorf B; Preti M; Jessen F; Franke A; Carambia A; Lohse AW; Ittrich H; Herkel J; Heeren J; Schramm C; Schwinge D
J Hepatol; 2019 Oct; 71(4):783-792. PubMed ID: 31207266
[TBL] [Abstract][Full Text] [Related]
23. Impaired bile acid handling and aggravated liver injury in mice expressing a hepatocyte-specific RXRα variant lacking the DNA-binding domain.
Kosters A; Felix JC; Desai MS; Karpen SJ
J Hepatol; 2014 Feb; 60(2):362-9. PubMed ID: 24120911
[TBL] [Abstract][Full Text] [Related]
24. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
Liao L; Schneider KM; Galvez EJC; Frissen M; Marschall HU; Su H; Hatting M; Wahlström A; Haybaeck J; Puchas P; Mohs A; Peng J; Bergheim I; Nier A; Hennings J; Reißing J; Zimmermann HW; Longerich T; Strowig T; Liedtke C; Cubero FJ; Trautwein C
Gut; 2019 Aug; 68(8):1477-1492. PubMed ID: 30872395
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.
Miethke AG; Zhang W; Simmons J; Taylor AE; Shi T; Shanmukhappa SK; Karns R; White S; Jegga AG; Lages CS; Nkinin S; Keller BT; Setchell KD
Hepatology; 2016 Feb; 63(2):512-23. PubMed ID: 26172874
[TBL] [Abstract][Full Text] [Related]
26. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
Moustafa T; Fickert P; Magnes C; Guelly C; Thueringer A; Frank S; Kratky D; Sattler W; Reicher H; Sinner F; Gumhold J; Silbert D; Fauler G; Höfler G; Lass A; Zechner R; Trauner M
Gastroenterology; 2012 Jan; 142(1):140-151.e12. PubMed ID: 22001865
[TBL] [Abstract][Full Text] [Related]
27. Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
Li J; Zhu X; Zhang M; Zhang Y; Ye S; Leng Y; Yang T; Kong L; Zhang H
J Hepatol; 2021 Aug; 75(2):400-413. PubMed ID: 33746084
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of p16 Decreases Biliary Damage and Liver Fibrosis in the Mdr2
Kyritsi K; Francis H; Zhou T; Ceci L; Wu N; Yang Z; Meng F; Chen L; Baiocchi L; Kundu D; Kennedy L; Liangpunsakul S; Wu C; Glaser S; Alpini G
Gene Expr; 2020 Nov; 20(2):89-103. PubMed ID: 32393417
[TBL] [Abstract][Full Text] [Related]
29. CsHscB Derived from a Liver Fluke
Yu Q; Koda S; Xu N; Li J; Wang JL; Liu M; Liu JX; Zhang Y; Yang HM; Zhang BB; Li XY; Li XC; Tang RX; Zheng KY; Yan C
Curr Mol Med; 2024; 24(4):505-515. PubMed ID: 37076961
[TBL] [Abstract][Full Text] [Related]
30. Protective effect of herbal medicine Huangqi decoction against chronic cholestatic liver injury by inhibiting bile acid-stimulated inflammation in DDC-induced mice.
Li WK; Wang GF; Wang TM; Li YY; Li YF; Lu XY; Wang YH; Zhang H; Liu P; Wu JS; Ma YM
Phytomedicine; 2019 Sep; 62():152948. PubMed ID: 31129431
[TBL] [Abstract][Full Text] [Related]
31. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis.
Fickert P; Stöger U; Fuchsbichler A; Moustafa T; Marschall HU; Weiglein AH; Tsybrovskyy O; Jaeschke H; Zatloukal K; Denk H; Trauner M
Am J Pathol; 2007 Aug; 171(2):525-36. PubMed ID: 17600122
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice.
Kim YC; Jung H; Seok S; Zhang Y; Ma J; Li T; Kemper B; Kemper JK
Hepatology; 2020 Jun; 71(6):2118-2134. PubMed ID: 31549733
[TBL] [Abstract][Full Text] [Related]
33. Nrf2 Ameliorates DDC-Induced Sclerosing Cholangitis and Biliary Fibrosis and Improves the Regenerative Capacity of the Liver.
Fragoulis A; Schenkel J; Herzog M; Schellenberg T; Jahr H; Pufe T; Trautwein C; Kensler TW; Streetz KL; Wruck CJ
Toxicol Sci; 2019 Jun; 169(2):485-498. PubMed ID: 30825315
[TBL] [Abstract][Full Text] [Related]
34. TGF-β2 silencing to target biliary-derived liver diseases.
Dropmann A; Dooley S; Dewidar B; Hammad S; Dediulia T; Werle J; Hartwig V; Ghafoory S; Woelfl S; Korhonen H; Janicot M; Wosikowski K; Itzel T; Teufel A; Schuppan D; Stojanovic A; Cerwenka A; Nittka S; Piiper A; Gaiser T; Beraza N; Milkiewicz M; Milkiewicz P; Brain JG; Jones DEJ; Weiss TS; Zanger UM; Ebert M; Meindl-Beinker NM
Gut; 2020 Sep; 69(9):1677-1690. PubMed ID: 31992593
[TBL] [Abstract][Full Text] [Related]
35. Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury.
Iruzubieta P; Goikoetxea-Usandizaga N; Barbier-Torres L; Serrano-Maciá M; Fernández-Ramos D; Fernández-Tussy P; Gutiérrez-de-Juan V; Lachiondo-Ortega S; Simon J; Bravo M; Lopitz-Otsoa F; Robles M; Ferre-Aracil C; Varela-Rey M; Elguezabal N; Calleja JL; Lu SC; Milkiewicz M; Milkiewicz P; Anguita J; Monte MJ; Marin JJG; López-Hoyos M; Delgado TC; Rincón M; Crespo J; Martínez-Chantar ML
JHEP Rep; 2021 Jun; 3(3):100276. PubMed ID: 33997750
[TBL] [Abstract][Full Text] [Related]
36. Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis.
Gao RY; Shearn CT; Orlicky DJ; Battista KD; Alexeev EE; Cartwright IM; Lanis JM; Kostelecky RE; Ju C; Colgan SP; Fennimore BP
Mucosal Immunol; 2021 Mar; 14(2):479-490. PubMed ID: 33004979
[TBL] [Abstract][Full Text] [Related]
37. 3,5-Diethoxycarbonyl-1,4-Dihydrocollidine Diet: A Rodent Model in Cholestasis Research.
Pose E; Sancho-Bru P; Coll M
Methods Mol Biol; 2019; 1981():249-257. PubMed ID: 31016659
[TBL] [Abstract][Full Text] [Related]
38. Caspase 8 differentially controls hepatocytes and non-parenchymal liver cells during chronic cholestatic liver injury in mice.
Chaudhary K; Liedtke C; Wertenbruch S; Trautwein C; Streetz KL
J Hepatol; 2013 Dec; 59(6):1292-8. PubMed ID: 23928400
[TBL] [Abstract][Full Text] [Related]
39. Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.
Gallucci GM; Trottier J; Hemme C; Assis DN; Boyer JL; Barbier O; Ghonem NS
Hepatol Commun; 2021 Dec; 5(12):2035-2051. PubMed ID: 34558841
[TBL] [Abstract][Full Text] [Related]
40. Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents.
Yu D; Cai SY; Mennone A; Vig P; Boyer JL
Liver Int; 2018 Jun; 38(6):1128-1138. PubMed ID: 29356312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
